Evidence map›Paper›PMID 40994644›Full record

ArticleFrontiers in pharmacology2025

Physician self-reported factors driving clinical decision-making in management of patients with T2D and ASCVD/high risk of ASCVD across the middle East and Africa: a cross-sectional study.

Sam Salek, Hani Sabbour, Naji Alamuddin, Fatheya Alawadi, Hessa Alkandari, Wael Almahmeed, Samir H Assaad-Khalil, Emel Mashaki Ceyhan, Jihad Haddad, Landman Lombard and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05317845 (A Multi-center, Cross-sectional Chart Review and Survey to Capture the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05317845 completednot on this map

A Multi-center, Cross-sectional Chart Review and Survey to Capture the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa

TypeobservationalSponsorNovo Nordisk A/SRan2022 to 2022Enrolled4,089ConditionsDiabetes Mellitus, Type 2ArmsNo treatment given
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sam SalekSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Hani SabbourHeart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Naji AlamuddinRoyal College of Surgeons in Ireland-Bahrain, King Hamad University Hospital, Adilya, Bahrain.
Fatheya AlawadiEndocrine Department, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates.
Hessa AlkandariDepartment of Pediatrics, Farwaniya Hospital, Kuwait City, Kuwait.
Wael AlmahmeedHeart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Samir H Assaad-KhalilUnit of Diabetes, Lipidology & Metabolism; Department of Internal Medicine/Alexandria Faculty of Medicine, Alexandria University, Egypt, Egypt.
Emel Mashaki CeyhanNovo Nordisk A/S, Søborg, Denmark.
Jihad HaddadEndocrinology Section, Bader Medical Complex, Amman, Jordan.
Landman LombardCape Town Medical Research Centre, Cape Town, South Africa.
Mary NgomeNovo Nordisk Saglik Urunleri Tic Ltd Sti, Istanbul, Türkiye.
Rayaz A MalikDepartment of Medicine, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar.
Gourav YadavNovo Nordisk Saglik Urunleri Tic Ltd Sti, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To explore factors influencing the clinical decision-making of physicians treating patients with type 2 diabetes (T2D) and high risk of atherosclerotic cardiovascular disease (ASCVD) across seven Middle Eastern and African countries. Methods: Cross-sectional, anonymous online study of self-reported factors driving clinical decision-making for the management of T2D based on agreement with statements using a five-point Likert scale among physicians (n = 385) in Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa, and UAE between June 13 and October 1, 2022. Results: From a selection of patient factors, physicians were most likely to agree that treatment adherence/compliance (92%), safety concerns (92%), and impact on health-related quality of life (88%) influenced their decision-making. Most physicians agreed that availability of treatment (87%) was a practice setting factor that influenced their decision-making. The top three physician factors influencing clinical decision-making included continuous medical education (96%), medical knowledge (96%), and international clinical guidelines (95%). Most physicians agreed that improved communication skills of physicians (97%), coaching and question prompts for patients (91%), and patient decision aids (87%) could improve shared decision-making. Conclusion: Various patient, practice, and physician factors influenced physicians' management of their patients with T2D. Physicians believed improving their communication skills could improve shared decision-making. Clinical Trial Registration: The trial is registered with clinicaltrails.gov, Identifier #NCT05317845 (2023-03-28).

Indexed as

atherosclerotic cardiovascular diseaseclinical decision-makingheart disease risk factorspublic health systems researchtype 2 diabetes

Identifiers

PMID40994644
PMCPMC12455046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.